Regeneron Looks To Use CRISPR Inside/Outside The Liver With Intellia Pact
This article was originally published in The Pink Sheet Daily
Under partnership with Intellia, Regeneron will use gene-editing technology to develop novel therapeutics against up to 10 targets, and will make a $50m equity investment in the biotech.
You may also be interested in...
Biopharma financing decreased by 16% in Q2 to $4.8 billion, while the total value of acquisitions nearly doubled to $22 billion, including AbbVie's $9.8 billion takeover of Stemcentrx. Alliances garnered an aggregate potential deal value of $23.1 billion, led by Allergan's CNS agreement with Heptares.
A review of biopharma start-up dealmaking and financing from April through June 2016, based on data from Strategic Transactions.
Genzyme’s decision to deepen its alliance with Alnylam plays to the strategic needs of both parties and to their complementary strengths. The agreement also was helped by the companies’ physical proximity and by a high-level conversation between Maraganore and Viehbacher at a critical juncture.